Breaking News Bar
updated: 7/7/2014 8:30 AM

SCID now part of newborn screening in Illinois

hello
Success - Article sent! close
  • Illinois newborn babies are now being screened for a rare disease called severe combined immunodeficiency.

      Illinois newborn babies are now being screened for a rare disease called severe combined immunodeficiency.
    File photo

 
Associated Press

DECATUR-- Illinois newborn babies are now being screened for a rare disease called severe combined immunodeficiency.

The (Decatur) Herald and Review reported Sunday that Illinois is the 18th state to test for SCID. It is a rare disorder that causes white blood cells to develop improperly.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Patients are susceptible to recurring infections and could develop pneumonia, meningitis or other complications. They can be treated with a stem-cell or bone-marrow transplant.

Dr. Mohammed A. Khan is a pediatric hospitalist at Decatur Memorial Hospital. He says babies with SCID have ongoing infections which are often fatal by the time SCID is diagnosed.

Newborns have blood drawn at least 24 hours after their first feeding and the state Department of Public Health tests the blood for a variety of diseases.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.